Additionally, an evaluation of the tumor mutation burden (TMB) showed that the IDH1 mutation was among the top 20 most frequent mutations in low-score GBMs, which correlated with better survival for patients with a low-risk score (Supplementary Figure S5L,M). Here, IDH1 is linked to neoplasm.